JP5167473B2 - 抗血管新生化合物 - Google Patents

抗血管新生化合物 Download PDF

Info

Publication number
JP5167473B2
JP5167473B2 JP2007558320A JP2007558320A JP5167473B2 JP 5167473 B2 JP5167473 B2 JP 5167473B2 JP 2007558320 A JP2007558320 A JP 2007558320A JP 2007558320 A JP2007558320 A JP 2007558320A JP 5167473 B2 JP5167473 B2 JP 5167473B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
unsubstituted
antibody
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007558320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531734A5 (enExample
JP2008531734A (ja
Inventor
ブラッドショー，カート・ダブリュー
ドッパラプディ，ヴェンカタ・ラマナ
ライ，ジン‐ユ
リッゾ，ジョン
Original Assignee
コヴェックス・テクノロジーズ・アイルランド・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コヴェックス・テクノロジーズ・アイルランド・リミテッド filed Critical コヴェックス・テクノロジーズ・アイルランド・リミテッド
Publication of JP2008531734A publication Critical patent/JP2008531734A/ja
Publication of JP2008531734A5 publication Critical patent/JP2008531734A5/ja
Application granted granted Critical
Publication of JP5167473B2 publication Critical patent/JP5167473B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
JP2007558320A 2005-03-03 2006-03-03 抗血管新生化合物 Expired - Fee Related JP5167473B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65865405P 2005-03-03 2005-03-03
US60/658,654 2005-03-03
US67708905P 2005-05-02 2005-05-02
US60/677,089 2005-05-02
PCT/US2006/007865 WO2006094269A2 (en) 2005-03-03 2006-03-03 Anti-angiogenic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012228959A Division JP2013056895A (ja) 2005-03-03 2012-10-16 抗血管新生化合物

Publications (3)

Publication Number Publication Date
JP2008531734A JP2008531734A (ja) 2008-08-14
JP2008531734A5 JP2008531734A5 (enExample) 2011-03-03
JP5167473B2 true JP5167473B2 (ja) 2013-03-21

Family

ID=36941895

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007558320A Expired - Fee Related JP5167473B2 (ja) 2005-03-03 2006-03-03 抗血管新生化合物
JP2012228959A Pending JP2013056895A (ja) 2005-03-03 2012-10-16 抗血管新生化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012228959A Pending JP2013056895A (ja) 2005-03-03 2012-10-16 抗血管新生化合物

Country Status (6)

Country Link
US (3) US20080152660A1 (enExample)
EP (2) EP2292248A3 (enExample)
JP (2) JP5167473B2 (enExample)
KR (1) KR101373140B1 (enExample)
CA (1) CA2598833A1 (enExample)
WO (1) WO2006094269A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040058229A (ko) * 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
JP5167473B2 (ja) * 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
EP2306986B1 (en) 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
WO2011094671A2 (en) * 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
US20130064838A1 (en) 2010-05-14 2013-03-14 Amgen Inc. Enhanced death receptor agonists
EP2593142B8 (en) 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Multifunctional antibody conjugates
RU2013118441A (ru) 2010-11-05 2014-12-10 КовЭкс Текнолоджиз Айэлэнд Лимитед Антидиабетические соединения
CA2822481A1 (en) 2011-01-03 2012-07-12 F. Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
PT3327027T (pt) 2011-11-17 2021-02-15 Pfizer Péptidos citotóxicos e seus conjugados de anticorpos e fármacos
CA2860109C (en) 2011-12-20 2016-08-09 Javier Magano Improved processes for preparing peptide conjugates and linkers
TWI560202B (en) 2011-12-22 2016-12-01 Pfizer Anti-diabetic compounds
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TW201341401A (zh) 2012-01-09 2013-10-16 Covx Technologies Ireland Ltd 突變抗體及其共軛
JP6219923B2 (ja) 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ
RU2618523C2 (ru) 2012-11-05 2017-05-04 Пфайзер Инк. Аналоги сплицеостатина
BR112015010436A2 (pt) 2012-11-07 2017-08-22 Pfizer Anticorpos anti-notch3 e conjugados anticorpo-fármaco
KR101871088B1 (ko) 2014-01-27 2018-06-25 화이자 인코포레이티드 이관능성 세포독성제
DK3242884T3 (da) * 2015-01-09 2021-04-19 Ipsen Bioinnovation Ltd Kationiske neurotoksiner
KR102046862B1 (ko) 2015-03-20 2019-11-20 화이자 인코포레이티드 Cti 약물작용발생단을 함유하는 이관능성 세포독성제
US11197934B2 (en) * 2015-09-17 2021-12-14 The Scripps Research Institute Dual variable domain immunoconjugates and uses thereof
TWI778491B (zh) 2015-11-30 2022-09-21 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
CA3012960A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
EP3617235A4 (en) 2017-04-28 2020-12-16 Ajinomoto Co., Inc. COMPOUND CONTAINING A SUBSTANCE HAVING AFFINITY FOR A SOLUBLE PROTEIN, CLIVABLE FRACTION, AND REACTIVE GROUP, OR SALT OF THE SAME
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
CN108066285B (zh) * 2017-11-30 2019-06-07 江南大学 一种肝靶向共输送基因/药物的整合纳米系统及制备方法
US20250312472A1 (en) * 2022-04-29 2025-10-09 University Of Florida Research Foundation, Incorporated Antibody compounds with reactive cysteine and related antibody drug conjugates

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) * 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
DE69126871T2 (de) 1990-04-06 1998-03-12 Jolla Cancer Res Found Verfahren und verbindung zur behandlung von thrombose
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6022542A (en) * 1995-09-26 2000-02-08 University Of Washington Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5932545A (en) * 1997-03-17 1999-08-03 Abbott Laboratories Antiangiogenic drug to treat cancer, arthritis and retinopathy
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
US6774211B1 (en) * 1998-05-22 2004-08-10 Abbott Laboratories Peptide antiangiogenic drugs
CO5080726A1 (es) 1998-05-22 2001-09-25 Abbott Lab Drogas antiangiogenicas basadas en peptidos
US6716963B1 (en) * 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
AU1190101A (en) 1999-09-27 2001-04-30 Regents Of The University Of California, The Engineering antibodies that bind irreversibly
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
DE60025648T2 (de) 1999-11-22 2006-09-14 Abbott Laboratories, Abbott Park Peptide mit antiangiogener aktivität
US6753408B1 (en) * 1999-11-22 2004-06-22 Fortuna Haviv Peptides having antiangiogenic activity
CO5261544A1 (es) 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica
JP2003514843A (ja) * 1999-11-24 2003-04-22 ザ リポソーム カンパニー、インコーポレーテッド モジュラー標的化リポソーム送達システム
US20020183242A1 (en) * 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20030045477A1 (en) * 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
KR20040058229A (ko) * 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2004091484A2 (en) * 2003-04-07 2004-10-28 Board Of Regents, The University Of Texas System Use of orsaponin [3beta, 16beta, 17 alpha-trihydroxycholost-5-en­22-one 16-0-(2-0-4-methoxybenzoyl-beta-d-xylopyranosyl)-(1->3)-(2-0­acetyl-alpha-l-arabinopyranoside)] or osw-1 and its derivatives for cancer therapeutics
WO2004091542A2 (en) * 2003-04-15 2004-10-28 Covx Pharmaceuticals, Inc. Nitrogen containing integrin targeting compounds
JP5167473B2 (ja) * 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物

Also Published As

Publication number Publication date
KR101373140B1 (ko) 2014-03-12
WO2006094269A2 (en) 2006-09-08
US20080152660A1 (en) 2008-06-26
AU2006218437A1 (en) 2006-09-08
KR20070108958A (ko) 2007-11-14
JP2013056895A (ja) 2013-03-28
JP2008531734A (ja) 2008-08-14
EP2292248A3 (en) 2011-06-29
US20060205670A1 (en) 2006-09-14
EP1853294A2 (en) 2007-11-14
EP2292248A2 (en) 2011-03-09
WO2006094269A3 (en) 2007-01-11
US20110087010A1 (en) 2011-04-14
EP1853294A4 (en) 2010-01-27
CA2598833A1 (en) 2006-09-08
US7521425B2 (en) 2009-04-21

Similar Documents

Publication Publication Date Title
JP5167473B2 (ja) 抗血管新生化合物
JP4897050B2 (ja) 抗血管形成化合物
KR101224335B1 (ko) 글루카곤-유사 단백질-1 수용기(ｇｌｐ-1ｒ) 작용제 화합물
RU2511420C2 (ru) Анти-ангиогенные соединения
AU2006218437B2 (en) Anti-angiogenic compounds
CN101287485A (zh) 抗血管生成化合物
AU2011202645B2 (en) Anti-angiogenic compounds
ES2369587T3 (es) Compuestos anti-angiogénicos.
HK1135416A (en) Glucagon-like protein-1 receptor (glp-1r) agonist compounds
HK1125290A (en) Anti-angiogenic compounds
HK1134099A (en) Anti-angiogenic compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110705

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111024

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121016

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121023

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121016

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20121121

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121122

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121128

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160111

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees